Summary Nitric oxide (NO), a biologically active mediator generated in many cell types by the enzyme NO synthase, may play an important role in cardiovascular toxicity that is frequently observed in cancer patients during intravenous (i.v.) interleukin 2 (IL-2) therapy. The induction of NO synthase and the production of NO seem to be involved in the pathogenesis of the vascular leakage syndrome, as well as in the regulation of myocardial contractility. In the present study, we evaluated the pattern of plasmatic NO changes during multiple cycles of continuous i.v. infusion (CIVI) of IL-2 in ten advanced cancer patients (five males, five females, median age 59 years, range 33-67 years; eight affected by renal cell cancer and two affected by malignant melanoma). The patients received IL-2 at 18 MIU m-2 day-' (14 cycles) or 9 MIU m-2 day-l (seven cycles) for 96 h, repeated every 3 weeks. Interferon alpha (IFN a) was also administered subcutaneously (s.c.) during the 3 week interval between IL-2 cycles. For each cycle, plasma samples were collected before treatment (to), 24 h (t,), 48 h (t2), 72 h (t3) and 96 h (t4) after the start of IL-2 infusion, and 24 h after the end of the cycle. NO concentration was determined spectrophotometrically by measuring the accumulation of both nitrite and nitrate (after reduction to nitrite). The following observations may be drawn from data analysis: (1) plasma nitrate + nitrite significantly raised during treatment (P = 0.0226 for to vs t3), but statistical significance was retained only when cycles administered with IL-2 18 MIU m-2 day-' are considered (P=0.0329 for to vs t3; P = 0.0354 for to vs t2 vs t4) (dose-dependent pattern); (2) during subsequent cycles a significant trend toward a progressive increase of plasma nitrate+ nitrite levels, with increasing cumulative dose of IL-2, was observed (linear regression coefficient r=0.62, P=0.0141 for to; r=0.80, P=0.0003 for tl; r=0.62, P=0.013 for t2; r=0.69, P=0.045 for t3); (3) plasma nitrate+nitrite levels peaked earlier in subsequent cycles than in the first cycle; (4) all patients experienced hypotension. The mean of the systolic blood pressure values was significantly lower at the time of plasma nitrate+nitrite peak than at to (P=0.0004); (5) the two cases of grade III hypotension occurred in patients with the higher mean and peak plasma nitrate+nitrite values. We conclude that determination of plasma nitrate + nitrite levels during CIVI IL-2 can usefully estimate, in a dose-dependent pattern, the degree of peripheral vascular relaxation and capillary leakage associated with cytokine action, clinically manifested as hypotension. However, isolated cardiac toxicity that continues to represent a relevant problem during IL-2 therapy, does not appear to correlate with plasma nitrate + nitrite levels; therefore, further studies are required to understand adequately the mechanisms underlying IL-2-induced cardiac toxicity.
Immunotherapy with interleukin 2 (IL-2) demonstrated clinical activity in the treatment of advanced renal cell carcinoma (RCC) (Linehan et al., 1993) and malignant melanoma (MM) (Balch et al., 1993) . Unfortunately, intravenous administration of IL-2 is associated with relevant cardiovascular side-effects: hypotension, fluid retention including pulmonary oedema, myocardial ischaemia and myocarditis (White et al., 1994; Osanto et al., 1988) . Renal and hepatic dysfunctions are also common (Margolin et al., 1989) . However, cardiovascular toxicity is the main doselimiting effect of IL-2 immunotherapy and evidence has been growing that nitric oxide (NO) may contribute to determine it (Ochoa et al., 1992; Miles et al., 1994) . NO is a biologically active mediator generated in many cell types by the enzyme NO synthase. Both a constitutive and an inducible isoform of this enzyme have been described. The former, expressed in vascular endothelium and neuronal tissue, plays a key role in modulating vascular tone and neurotransmission (Moncada and Higgs, 1993) . The latter can be induced by a number of cytokines in different tissues (Hibbs et al., 1992) . The induction of NO synthase in vessel walls is responsible for the vasodilation and resistance to vasoconstrictors characteristic of septic shock (Wang et al., 1994; Kilbourn et al., 1995; Meyer et al., 1994; Petros et al., 1994) , as well as the hypotension induced by cytokine therapy in cancer patients (Miles et al., 1994) . More recently, NO has also been shown to be involved in the control of myocardial contractility (Finkel et al., 1992; De Belder et al., 1993; Paulus et al., 1994) . High concentrations of NO, generated by the inducible isoform of NO synthase, have been associated with impaired myocardial performance in a number of inflammatory heart diseases (De Belder et al., 1993) .
As IL-2 plays a central role in cell-mediated immunity and is the key factor for the induction of a complex network of cytokines, one could suggest that IL-2-mediated NO generation by inducible NO synthase may contribute to the cardiac adverse effects observed during immunotherapy, as well as to hypotension. The aim of this study was to determine the pattern of plasma NO changes, measured as plasma nitrate + nitrite values during a number of continuous intravenous infusions (CIVI) of IL-2, and to look for correlations with the cardiovascular toxic side-effects observed.
Materials and methods Patients
The study included ten patients (five men, five women; median age 59 years, range 33 -67 
t3; P=0.0354 for to vs t2 vs 14), while a non-significant minimal increase was noted in cycles at half-dose IL-2 (see Table II ).
Plasma nitrate + nitrite changes were determined in multiple cycles. A trend towards increase of plasma nitrate+ nitrite levels with cumulative dose of IL-2 was observed: linear regression coefficient r = 0.62 (P= 0.014) for to; r = 0.80 (P=0.0003) for tl; r=0.62 (P=0.013) for t2; r = 0.69 (P = 0.045) for t3 (see Table III ). Moreover, the peak of plasma nitrate + nitrite was reached more rapidly from the start of IL-2 infusion in subsequent cycles with respect to the first cycle: 6/6 IL-2 infusions as first cycle had peak of plasma nitrate+ nitrite at > 72 h, while 5/6 IL-2 infusions as second cycle and 3/3 IL-2 infusions as third cycle showed plasma nitrate + nitrite peak at < 48 h (P = 0.003). During IL-2 administration, arterial pressure (AP) was monitored every 2 h, and all patients experienced hypotension, presumably related to the vascular leakage syndrome. The mean of systolic AP values obtained at the time of plasma nitrate + nitrite peak for each cycle was significantly lower than that observed at to: 119.76+3.66 vs 137.14+2.98 mmHg (P=0.0004). Figure 1 shows the related changes of mean plasmatic nitric oxide and systolic blood pressure for all cycles.
Considering the whole groups of cycles, IL-2 administration had to be interrupted in six cases (6/14 in the high-dose vs 0/7 in the low-dose group, P = 0.040): five interruptions were due to cardiovascular toxic side-effects (two cases of grade III hypotension, two ischaemic ECG changes, one pulmonary oedema). In one case chest pain was complained of but neither ECG nor cardiac enzymes changed. The two cases of grade III hypotension occurred in the second and fourth cycle in the patient with the highest mean and peak plasma nitrate + nitrite values (77.35 and 115 ,mol 1-' respectively vs 55.46 and 93 ,umol 1-1 for the whole group of remaining patients, P=0.038 for means). In the second cycle, the plasma nitrate+nitrite value before the hypotension was 53.6 ymol 1`and the basal value was 39.9 umol 1-' (34.3% rise from basal value). In the fourth cycle, the plasma nitrate + nitrite value before the hypotension was 99.6,mol 1`and the basal value was 82.4 4umol 1-1 (20.9% rise from basal value). No significant differences were found in the degree of rise in plasma nitrate + nitrite from basal smooth muscle relaxation, is produced in increased amounts by numerous cell types, particularly endothelial cells, after exposure to a number of inflammatory cytokines, and it is at least partly responsible for IL-2 mediated hypotension, as the haemodynamic effects induced by IL-2 administration are reserved by NG-methyl-L-arginine, a NO synthesis inhibitor (Ochoa et al., 1992; Kilbourn et al., 1995) . Moreover, NO has direct effects on myocardium. In an experimental model, the infusion of a NO donor into the global coronary arterial bed of the left ventricle (LV) resulted in a significant reduction in LV peak and endsystolic pressures, an earlier onset of LV isovolumic relaxation and increased LV diastolic distensibility (Paulus et al., 1994) . Recently, plasma NO measured as nitrate + nitrite determination was showed to increase during CIVI IL-2 at the dose of 18 MIU m-2 day-' for 5 days, reaching maximal concentrations on day 5, and was related to maximal TNF-a and IFN-y levels (Miles et al., 1994) . Our results are consistent with previous observations: plasma nitrate+nitrite levels increase during IL-2 infusion in a dose-dependent pattern, so that only when IL-2 was given at 18 MIU m-2 day-' a significant nitrate+ nitrite elevation was observed, while a half-dose of IL-2 does not seem to induce similar nitrate+nitrite changes. Moreover, a cumulative effect of IL-2 was also noted: 3 week interval between consecutive IL-2 cycles does not terminate the biological effect of the cytokine, as a trend toward higher plasma nitrate+nitrite values through subsequent IL-2 cycles was noted. This may be partly because of the ability of IL-2 to elicit immunological reactions with secondary cytokine production. All patients received IFN-a during intervals between IL-2 cycles: an effect of this biological response modifier cannot be excluded, although direct correlation between IFN-a therapy and NO synthase activation has not been reported. Cardiovascular side-effects represent a relevant problem to deal with during i.v. IL-2 treatment, as they cause the majority of transient or definitive IL-2 interruptions. In our series of 224 consecutive IL-2 infusions, 78 (34.8%) were interrupted owing to toxic events. In particular, 21/78 (26.9%) cycles were interrupted because of grade III-IV hypotension, while 24/78 (30.1%) interruptions were determined by cardiac events (i.e. myocardial ischaemia; arrhythmias such as atrial fibrillation, supraventricular tachyarrhythmias, grade II atrial-ventricular block; myocarditis) (unpublished data). As NO production and release is involved either in vascular muscle dilation (Moncada et al., 1991) or in direct myocardial damage (Paulus et al., 1994) , NO plasma concentration might correlate both with vascular and cardiac toxic events. Moreover, in a subset of 31 cycles in which echocardiography was routinely performed before and after each IL-2 infusion, a number of subclinical echocardiographic abnormalities were found, mainly regarding LV diastolic impairment, possibly suggesting a pathogenetic role of NO in damaging myocardial tissue (Di Lucca et al., 1995) . In the present study, plasma nitrate+nitrite levels correlate with hypotension, as already shown (Miles et al., 1994) , while no association was found between plasma nitrate + nitrite levels and the cardiac toxic events observed (two ischaemic ECG changes and one cardiogenic pulmonary oedema). This seems to suggest that NO is not the final mediator of myocardial damage where cardiac toxicity is concerned. Alternatively, the local release of NO via the inflammatory cascade of cytokines initiated by IL-2 might be enough to determine impairment of ventricular function, without a release in systemic circulation to levels detectable by plasma sampling. A more complex and invasive experimental design (e.g. intra right atrium blood sampling) would be needed to get full insight into this tissue.
In conclusion, the determination of plasma nitrate + nitrite levels during CIVI IL-2 can provide a useful estimate of the degree of peripheral vascular relaxation and capillary leakage associated with cytokine action, clinically manifested as hypotension. A dose-dependent pattern and course-dependent pattern for plasma nitrate+nitrite changes have been well established. However, isolated cardiac toxicity, which continues to represent a relevant problem during IL-2 therapy, does not appear to be predicted by plasma nitrate + nitrite changes. The mechanisms of this therapylimiting toxicity require further studies, so that clinicians could reliably predict and adequately prevent cardiac events related to IL-2 infusions.
